ENDRA Life Sciences (NASDAQ:NDRA) Announces Quarterly Earnings Results

ENDRA Life Sciences (NASDAQ:NDRA) released its earnings results on Friday. The company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.67) by $0.92, Zacks reports.

ENDRA Life Sciences Price Performance

NASDAQ:NDRA traded up $0.13 during midday trading on Friday, reaching $6.70. 25,634 shares of the company traded hands, compared to its average volume of 91,418. ENDRA Life Sciences has a twelve month low of $2.90 and a twelve month high of $11.96. The firm has a market capitalization of $5.03 million, a price-to-earnings ratio of -0.20 and a beta of -0.09. The company has a fifty day moving average price of $5.53 and a 200 day moving average price of $4.93.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NDRA shares. Wall Street Zen cut shares of ENDRA Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ENDRA Life Sciences currently has an average rating of “Hold” and an average price target of $50.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.